TY - JOUR
T1 - Racial differences in systemic sclerosis disease presentation
T2 - A European Scleroderma Trials and Research group study
AU - Jaeger, Veronika K.
AU - Tikly, Mohammed
AU - Xu, Dong
AU - Siegert, Elise
AU - Hachulla, Eric
AU - Airò, Paolo
AU - Valentini, Gabriele
AU - Cerinic, Marco Matucci
AU - Distler, Oliver
AU - Cozzi, Franco
AU - Carreira, Patricia
AU - Allanore, Yannick
AU - Müller-Ladner, Ulf
AU - Ananieva, Lidia P.
AU - Balbir-Gurman, Alexandra
AU - Distler, Jörg H.W.
AU - Czirják, Laszlo
AU - Li, Mengtao
AU - Henes, Jörg
AU - Jimenez, Sergio A.
AU - Smith, Vanessa
AU - Damjanov, Nemanja
AU - Denton, Christopher P.
AU - DelGaldo, Francesco
AU - Saketkoo, Lesley Ann
AU - Randone, Silvia Bellando
AU - Bannert, Bettina
AU - Iannone, Florenzo
AU - Maurer, Britta
AU - Jordan, Suzana
AU - Dobrota, Rucsandra
AU - Becker, Mike
AU - Mihai, Carina
AU - Becvarare, Radim
AU - Tomcik, Michal
AU - Bielecka, Otylia Kowal
AU - Gindzienska-Sieskiewicz, Ewa
AU - Karaszewska, Katarzyna
AU - Cutolo, Maurizio
AU - Pizzorni, Carmen
AU - Paolino, Sabrina
AU - Sulli, Alberto
AU - Ruaro, Barbara
AU - Alessandri, Elisa
AU - Riccardi, Antonella
AU - Herrmann, Kristine
AU - Kahl, Sarah
AU - Riemekasten, Gabriela
AU - Sommerlatte, Sabine
AU - EUSTAR co-authors
AU - Arnold, Sabrina
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.
AB - Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.
UR - http://www.scopus.com/inward/record.url?scp=85088708108&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kez486
DO - 10.1093/rheumatology/kez486
M3 - Journal articles
C2 - 31680161
AN - SCOPUS:85088708108
SN - 1462-0324
VL - 59
SP - 1684
EP - 1694
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 7
ER -